论文部分内容阅读
一、对肿瘤无直接作用的生物反应修饰剂(BRM)近年,生物反应修饰剂作为免疫疗法的药物和手段受到极大重视,其中包括一直作为免疫疗法研究中心的免疫激活剂。BRM 的第1期临床研究的主要目标是探讨其毒性、最大耐量和激活机体抗癌免疫功能的最适剂量。因其基础和临床的研究方法和标准尚未确立,许多问题有待深入探讨。BRM 并无直接缩小肿瘤的效果。目前正在进行Ⅱ、Ⅲ期研究,以确定BRM 的有效性。判定卡介苗、诺卡氏菌属细胞壁骨架(N-CWS)、OK-432等抗肿瘤临床效果的各种试验,目前也正在进行,但其涉及问题较多,难度较大。
First, biological response modifiers (BRMs) that have no direct effect on tumors. In recent years, biological response modifiers have received great attention as immunotherapeutics drugs and means, including immunostimulants that have been the center of immunotherapy research. The primary goal of the Phase 1 clinical study of BRM is to investigate its toxicity, maximal tolerance, and optimal dose to activate the body’s anti-cancer immune function. Because its basic and clinical research methods and standards have not yet been established, many issues need to be further explored. BRM does not directly reduce the effect of tumors. Phase II and III studies are currently underway to determine the effectiveness of BRM. Various tests to determine the anti-tumor clinical effects of BCG, Nocardia, and OK-432 are currently underway, but they involve more problems and are more difficult.